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Hyperkalemia contributes to significant mortality and
limits the use of cardioprotective and renoprotective
renin–angiotensin–aldosterone blockers. Current therapies
are poorly tolerated and not always effective. Here we
conducted a phase 2 randomized, double-blind, placebo-
controlled dose-escalation study to assess safety and
efficacy of ZS-9. This oral selective cation exchanger that
preferentially entraps potassium in the gastrointestinal tract
was given to patients with stable Stage 3 chronic kidney
disease and hyperkalemia (5.0 to 6.0mEq/l) during a 2-day
period. Of 90 eligible patients with mean baseline serum
potassium of 5.1mEq/l, 30 were randomized to placebo,
12–0.3g, 24–3g, or 24 to 10g of ZS-9 three times daily for 2
days with regular meals. None withdrew and ZS-9 dose-
dependently reduced serum potassium. The primary efficacy
end point (rate of serum potassium decline in the first 48h)
was met with significance in the 3- and 10-g cohorts. From
baseline, mean serum potassium was significantly decreased
by 0.92±0.52mEq/l at 38h. Urinary potassium excretion
significantly decreased with 10-g ZS-9 as compared to
placebo at day 2 (þ 15.8 þ / 21.8 vs. þ 8.9 þ / 22.9 mEq
per 24h) from placebo at day 2. In this short-term study, no
serious adverse events were reported; only mild constipation
in the 3-g dose group was possibly related to treatment.
Thus, ZS-9 was well-tolerated in patients with stable chronic
kidney disease and hyperkalemia leading to a rapid,
sustained reduction in serum potassium.
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Hyperkalemia is an independent risk factor for mortality in
patients with cardiovascular disease, chronic kidney disease
(CKD), and end-stage renal disease,1–5 and it limits the use of
renin–angiotensin–aldosterone system (RAAS) inhibitors in
the populations expected to derive the most benefit from
this drug class.6 Despite the need for safe, effective, and
predictable hyperkalemia treatment, current treatment
options remain limited.7
Sodium polystyrene sulfonate (SPS; Kayexalates) is the
only product approved in the United States to treat hyper-
kalemia.7–9 Kayexalate is an organic polymer resin that
nonselectively binds potassium (Kþ ) and other divalent
cations (e.g., calcium (Ca2þ ), magnesium (Mg2þ )), and
subsequently removes them via defecation, often stimulated
by the additive sorbitol (a laxative and cathartic).8,10 Despite
its long history of use, Kayexalate has never been evaluated in
a randomized, prospective, placebo-controlled setting.11–13 Its
association with poor gastrointestinal tolerability and other
substantial adverse events (AEs; e.g., sodium loading, hypo-
calcemia, hypomagnesemia, colonic necrosis)8,14–16 makes it
unsuitable for chronic administration.
Zirconium is a biologically inert trace element found
widely in nature; estimated human dietary intake is B4mg
daily.17 Partly owing to their inertness, zirconium-containing
compounds have been used extensively in biomedical appli-
cations,18 including hemodialysis with sorbent regenera-
tion.19–21 Sodium zirconium cyclosilicate (ZS-9), unlike
traditional organic polymers such as Kayexalate and the
investigational agent patiromer, was engineered with a highly
selective, high-capacity inorganic crystalline lattice structure
that preferentially entraps monovalent cations (specifically
Kþ and ammonium (NH4
þ )) over divalent cations (e.g.,
Ca2þ and Mg2þ ) in the gastrointestinal tract.22,23 Thermo-
dynamic modeling studies have estimated that Kþ -binding
of ZS-9 is 20.4 kcal/mol more stable than its native sodium-
bound form, thus enabling the exchange of Kþ for Naþ
(data on file, ZS Pharma). As a zirconium silicate crystal,
ZS-9 is completely insoluble in aqueous solutions24 and is
not systemically absorbed following oral ingestion, based on
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99% recovery of zirconium in feces of ZS-9-treated rats
(Supplementary Figure S1 online). ZS-9 also increases fecal
excretion of Kþ and reduction of urinary Kþ in rats
(Supplementary Figure S2 online).
Here we report results from the first-in-human study with
ZS-9, a randomized, double-blind, placebo-controlled Phase
2 study to assess safety and efficacy of the oral sorbent ZS-9
in hyperkalemia patients with Stage 3 CKD.
RESULTS
Patient demographics and disposition
The study was conducted at nine US sites (November
2011–May 2012). Ninety patients met all eligibility criteria
and were randomized 2:1 to receive ZS-9 (0.3 g (n¼ 12), 3 g
(n¼ 24), and 10 g (n¼ 24)) or placebo (n¼ 30). All rando-
mized patients completed the study as per protocol, and
they are included in the primary efficacy and safety analyses
(Figure 1).
Treatment groups were well-balanced with regard to
baseline demographics, except that there were more men in
the placebo group than in the ZS-9 groups (Table 1). Across
groups, 56% of patients had a history of diabetes at baseline;
62% were receiving a RAAS inhibitor (Table 1).
Treatment exposure
All patients received the protocol-specified minimum dose
(six doses) of the study drug in the initial 48-h treatment
period. None in the 10-g ZS-9 group required treatment
beyond 48 h. Continued treatment was required on day 3
(doses seven to nine) in placebo (30.0%), 0.3-g (16.7%), and
3-g (12.5%) patients, and on day 4 (doses 10–12) in placebo
(10.0%) and 0.3-g (8.3%) patients.
Serum potassium
ZS-9 dose-dependently reduced in serum Kþ (s-Kþ ); the
primary efficacy end point was met in the 3-g (P¼ 0.048)
and 10-g (Po0.0001) dose groups versus placebo (Figure 2).
In the 10-g ZS-9 group, mean s-Kþ decreased significantly
from baseline by 0.11mEq/l at 1 h after the first dose
(P¼ 0.02 vs. placebo). Greater mean reductions in s-Kþ were
seen on day 2 (Hour 28 to 48) with 10-g ZS-9 versus placebo
(Pp0.001), achieving a maximum reduction of 0.92mEq/l at
38 h (Po0.001; Table 2, Figure 3). At Hour 38, 41.7% of
patients on 10-g ZS-9 versus 3.4% on placebo had a
41.0mEq/l drop in s-Kþ . The last dose in the 10-g ZS-9
group was administered on day 2, yet s-Kþ remained
significantly lower than placebo for 3.5 additional days (i.e.,
Hour 120; Figure 3).
Mean s-Kþ changes in the subgroup of patients on RAASi
therapy were consistent with the changes in the overall
population (Table 2). The primary efficacy end point was met
in the 10-g ZS-9 dose group versus placebo (Po0.0001) in
this subgroup.
Other serum and urine parameters
Twenty-four-hour urinary Kþ excretion declined significantly
in the 10-g ZS-9 group relative to placebo ( 15.8 vs. þ
8.9mEq/24-h; Po0.001) at day 2 (Figure 4a). There were no
apparent differences in 24-h urinary sodium excretion
between placebo and any ZS-9 dose (Figure 4b).
Baseline blood urea nitrogen was higher than placebo in
the 10-g ZS-9 group (P¼ 0.01) and similar in the other
groups. There was evidence of a dose-related effect of ZS-9
on blood urea nitrogen; the greatest effect was in the 10-g
group, with baseline decreases differing significantly from
placebo at all measurements in days 2–7 (Figure 5a). Serum
bicarbonate increasedB10% with 10-g ZS-9, from 27.4mmol/
l at baseline to 30.1mmol/l on days 2 (P¼ 0.05) and 3
(P¼ 0.067; Figure 5b).
There were no clinically relevant changes in serum Ca2þ ,
Mg2þ , or Naþ or in kidney function parameters (serum
creatinine (Figure 5c), 24-h urea nitrogen, urine creatinine,
and urinary sediment), nor were there any significant
changes in systolic and diastolic blood pressure across dose
groups (Figure 6).
Safety
ZS-9 was well-tolerated; across the placebo and the 0.3-, 3-,
and 10-g ZS-9 groups, X1 treatment-emergent AE occurred
in 3 (10%), 1 (8%), 3 (13%), and 8 (33%) patients (Table 3).
The investigators rated all treatment-emergent AEs mild or
moderate; most were transient and did not require treatment.
No serious AEs were reported. No AEs led to study
discontinuation. Three treatment-emergent AEs were con-
sidered to be possibly related to the study treatment: mild
constipation (3 g ZS-9), and mild nausea and mild vomiting
(placebo). No patients had any notable changes in bowel
movement frequency or stool appearance.
Screened
N = 183
1.
2.
3.
4.
5.
6.
Randomized
N = 90
Screen failures (n = 93)
Serum K+ not between 5.0–6.0
mEq/L on day 0 (n = 69)
eGFR not between 30–60 ml/min
(n = 7) 
Both serum K+ and eGFR inclusion
criteria not met (n = 12) 
Withdrew consent (n = 2)
Cancer within last 5 yrs (n = 1)
Investigator decision (n = 2)
ZS-9 10.0g
n = 24 
ZS-9 3.0g
n = 24 
ZS-9 0.3g
n = 12
Placebo
n = 30
All patients completed study drug treatment per protocol and received
at least 2 full days of study medication 
9 patients
received 3d;
3 patients
received 4d
2 patients
received 3d;
1 patient
received 4d
3 patients
received 3d;
no patients
received 4d
No patients
received
more than 2d
Figure 1 | Patient disposition. eGFR, estimated glomerular filtration
rate; ZS-9, sodium zirconium cyclosilicate.
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No cases of significant hypocalcemia (p8.0mg/dl), hypo-
magnesemia (p1.2mEq/l), or hypokalemia (o3.0mEq/l)
were reported. ZS-9 had no dose-related effects on serum
glucose, blood pressure, heart rate, or other vital signs.
DISCUSSION
These results demonstrate that oral ingestion of ZS-9 with
meals significantly lowered s-Kþ in patients with stage 3
CKD. The 10-g dose of ZS-9 rapidly and substantially
reduced mean s-Kþ : (1) levels were 0.92mEq/l below
baseline after 38 h of treatment (Po0.001), and (2) levels
remained significantly lower than placebo for up to 3.5 days
after the last dose. The 3-g dose also significantly reduced the
mean s-Kþ in the first 48 h of treatment, although the time
to effect was longer and the overall magnitude of the change
was smaller compared with the 10-g dose.
The rapid and significant fall in mean s-Kþ by 0.92mEq/l
after 38 h of treatment with the 10-g dose of ZS-9 is clinically
relevant in the context of hyperkalemia; a decline ofX1mEq/
l at 48 h in postcritical care may eliminate the significant
association between high Kþ levels and mortality.3 Although
s-Kþ levels remained lowered for up to 3.5 days after the last
10-g ZS-9 dose, they increased gradually after treatment
discontinuation, emphasizing the need for maintenance
treatment in CKD and hyperkalemia patients. Of note,
mean s-Kþ also decreased slightly with placebo at 8 and
14 h after the first dose (Table 1), after which s-Kþ levels
varied widely, but never decreased below 4.8mEq/l (Figure 3).
A s-Kþ reduction in patients entering an inpatient facility
is not unexpected, given that their in-center diet, although
unrestricted, likely differed from their usual home diet. In
animal studies, ZS-9 was effective when given with food, and
it did not affect food consumption or weight (data on file, ZS
Pharma). ZS-9 was administered with meals in the present
study to mimic the use of the compound in a real-world
setting. It seems unlikely that changes in dietary Kþ intake
influenced the efficacy conclusions for the following reasons:
first, the between-group difference was maintained at nearly
Table 1 | Baseline demographic and clinical characteristics
ZS-9 dose group
Parameter Placebo (N¼ 30) 0.3 g (N¼ 12) 3g (N¼ 24) 10g (N¼ 24)
Demographics
Age, year 69.7±11.0 70.3±6.9 72.0±6.3 72.3±11.7
Male, n (%) 23 (77) 6 (50) 14 (58) 9 (38)
White, n (%) 29 (96.7) 12 (100.0) 24 (100.0) 23 (95.8)
Weight, kg 95.2±22.1 84.8±18.0 89.0±22.0 86.6±26.3
Eligibility criteria
Serum potassium, mEq/la 5.1±0.4 5.2±0.3 5.0±0.3 5.1±0.4
eGFR, ml/min per 1.73m2 58.1±26.5 56.5±24.0 57.1±22.1 51.6±22.3
History of diabetes, n (%) 19 (63.3) 7 (58.3) 13 (54.2) 11 (45.8)
Serum glucose, mg/dl 161.4±66.1 123.4±41.3 127.8±40.7 126.3±34.3
Serum creatinine, mg/dl 1.5±0.3 1.4±0.2 1.4±0.2 1.4±0.3
24-h urinary potassium, mEq/day 56.5±34.0 62.4±31.5 58.9±20.4 46.9±23.7
Serum sodium, mEq/l 139.4±2.8 139.1±3.7 140.0±3.1 137.7±3.5
Any concomitant RAAS blocker, n (%) 15 (50) 9 (75) 16 (67) 16 (67)
ACE-I only 11 (37) 6 (50) 12 (50) 13 (54)
ARB only 2 (13) 3 (33) 1 (13) 3 (29)
Spironolactone only 2 (13) 0 (0) 3 (17) 0 (0)
Dual therapy (ACE-IþARB or ACE-I or ARBþ spironolactone) 3 (10) 1 (8) 2 (8) 4 (17)
Diuretic use, n (%) 8 (26.7) 2 (16.7) 11 (45.8) 9 (37.5)
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; eGFR, estimated glomerular filtration rate; Kþ , potassium; ZS-9, sodium
zirconium cyclosilicate.
Data are presented as mean±s.d. unless otherwise noted.
aMean baseline serum potassium level was calculated for each patient on the basis of an average of four samples: 3 different samples were collected at 30-min intervals on
Study Day 1, and one sample was collected on Study Day 1 before the initial dose of the study drug.
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Figure 2 | Rate of decline in serum potassium over the first 48 h
of treatment with 0.3-g (n¼ 12), 3-g (n¼ 24), and 10-g ZS-9
(n¼ 24) or placebo (n¼ 30)—intent-to-treat population. This
model prediction uses every serum Kþ data point from each patient.
Although the rate of decline is actually a curve, during the 48-h time
frame of interest, it appears linear as presented here. The plotted
rates of decline in serum Kþ also visually illustrate the dose–response
relationship. Triangles indicate study drug administration (six doses in
34 h). ZS-9, sodium zirconium cyclosilicate.
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all time points to Day 6 (Figure 3), and, second, any changes
in dietary Kþ intake would likely have occurred across treat-
ment groups in this double-blind study. In line with these
findings, 24-h urinary Kþ excretion declined significantly by
24.7mEq/day with 10-g ZS-9 at day 2 compared with placebo
(Figure 4a). Over the 2-day trial, the cumulative difference
in urinary potassium excretion between placebo and the
10-g-treated group was approximately 40mEq.
Table 2 | Serum Kþ at baseline and change from baseline during the on-drug evaluation periods on Day 1 and 2 (up to 4 h after
the last dose on each day): ITT population (A) and subgroup on concomitant RAAS therapy (B)
ZS-9 dose group
Serum Kþ (mEq/l) Placebo 0.3g 3g 10g
A. ITT population n¼ 30 n¼ 12 n¼ 24 n¼ 24
Baseline 5.14±0.36 5.22±0.26 5.02±0.32 5.05±0.36
Day 1
Hour 0.5 0.03±0.31 0.05±0.32 0.06±0.42  0.02±0.24
Hour 1 0.12±0.36 0.01±0.46 0.00±0.47  0.11±0.46 (P¼ 0.04)
Hour 2  0.02±0.34 0.14±0.37 0.03±0.47  0.13±0.35
Hour 4  0.16±0.54  0.16±0.36  0.09±0.47  0.25±0.41*
Hour 8  0.24±0.46*  0.08±0.52  0.23±0.49*  0.37±0.38*
Hour 14  0.32±0.50*  0.31±0.41*  0.35±0.47*  0.55±0.47*
Day 2
Hour 0  0.17±0.43*  0.32±0.37*  0.36±0.36*  0.32±0.48*
Hour 4  0.10±0.40  0.25±0.29*  0.22±0.44*  0.52±0.49 (P¼ 0.001)*
Hour 8  0.11±0.43  0.18±0.39  0.29±0.48*  0.62±0.45 (Po0.001)*
Hour 14  0.26±0.4*  0.39±0.4*  0.42±0.45*  0.92±0.52 (Po0.001)*
B. RAAS subgroup n¼ 18 n¼ 10 n¼ 18 n¼ 20
Baseline 5.2±0.4 5.2±0.3 5.1±0.3 5.1±0.4
Day 1
Hour 0.5  0.07±0.29 0.11±0.31 0.05±0.45  0.02±0.26
Hour 1 0.19±0.31  0.01±0.51  0.04±0.51  0.12±0.50 (Po0.03)
Hour 2 0.01±0.39 0.11±0.39 0.00±0.44  0.19±0.26
Hour 4  0.19±0.60  0.17±0.39  0.13±0.48  0.33±0.35
Hour 8  0.21±0.54  0.03±0.57  0.16±0.52  0.34±0.41
Hour 14  0.31±0.60  0.28±0.44  0.27±0.48  0.61±0.49
Day 2
Hour 0  0.20±0.49  0.39±0.29  0.40±0.35  0.43±0.43
Hour 4  0.12±0.45  0.26±0.32  0.17±0.46  0.60±0.44 (P¼ 0.002)
Hour 8  0.13±0.48  0.19±0.43  0.23±0.48  0.74±0.35 (Po0.001)
Hour 14  0.25±0.46  0.49±0.38  0.32±0.48  1.05±0.47 (Po0.001)
Abbreviation: ZS-9, sodium zirconium cyclosilicate.
Values are mean±s.d. P-values shown in the table were calculated using unpaired t-tests based on differences with the placebo group; P-values are provided only when
the differences compared with placebo were significant (Po0.05). Asterisks denote Po0.05 for comparisons against baseline. The P-values listed in the table refer to
comparisons against placebo.
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ZS-9 binds both NH4
þ and Kþ in vitro, owing to
compatible ionic diameters with ZS-9 pore size. Consistent
with ZS-9 binding of NH4
þ , small increases in serum
bicarbonate levels were observed in patients on ZS-9 (3mEq/l
with 10-g dose), as well as a significant decrease in blood urea
nitrogen. Intravenous sodium bicarbonate has been used as a
treatment for patients with marked hyperkalemia and
acidosis, but most studies have shown that the effect of this
therapy is small, yielding anB0.1mEq/l decrease in s-Kþ for
each 1mEq/l increase in serum bicarbonate—after account-
ing for extracellular fluid volume changes.25–28 Other studies
have demonstrated that changes in serum bicarbonate have
no effect on s-Kþ levels.29–31 Correction of acidosis has
been shown to diminish the rate of progression of renal
disease.24,32 The ability of ZS-9 to elicit additional kidney-
protective effects via persistent improvement of acid–base
balance warrants further study.
Factors related to diabetes control or compliance with
concomitant medications (e.g., loop or thiazide diuretics)
may also have contributed to s-Kþ decreases in the placebo
group. The distribution of patients with diabetes and on
diuretics was comparable across treatment groups, and there
was no evidence of a dose-related effect of ZS-9 on blood
glucose.
ZS-9 treatment was well-tolerated. AE rates were compar-
able to placebo at 0.3- and 3-g ZS-9. AE rates were higher
with 10-g ZS-9, primarily related to a higher incidence of
Placebo (n = 30)
10 g ZS-9 (n = 24)
*P < 0.01 for 10 g vs. placebo.
P = NS for 10 g vs. placebo.
8.2
24.4 26.3
36.9
25.4
Day 2Day 1Baseline
Time (day)
8.9
–6.0
–15.8
*
*
Figure 4 |Mean change from baseline in 24-h urinary excretion of
potassium (a) and sodium (b). *Indicates significant difference
compared with placebo. NS, not significant; ZS-9, sodium zirconium
cyclosilicate.
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gastrointestinal-related events (seven events in four patients);
however, most of the events were transient and mild.
Screening urinalysis was positive for bacterial culture in
three patients with urinary tract infection reported as AEs
with ZS-9; the patients’ clinical conditions did not worsen
during the study. No sodium loading was observed with
ZS-9. There was no evidence of worsening hypertension or
fluid retention. The present study evaluated the effects
of ZS-9 t.i.d. for 2 days (and up to two more days if
s-Kþ X5.0mEq/l), and thus it does not provide information
on chronic treatment with less frequent daily dosing.
A recently completed, two-stage (acute and extended) phase
3 study (n¼ 753) evaluated ZS-9 once daily for up to 12 days
in patients with hyperkalemia (with or without CKD) who
achieved normokalemia in the acute phase; the results will
provide data on the safety and efficacy profile of ZS-9 in the
extended treatment setting.
The relatively small number of patients per treatment arm
is a limitation to the current study; still, the consistency of
the efficacy end points in the overall population and the
RAAS subgroup, dose response, and compelling P-values
suggest that a true treatment effect was observed. The
Kþ content of meals was not measured; the degree to
which dietary Kþ affects s-Kþ levels during ZS-9 treat-
ment remains to be determined. Few patients had s-Kþ
45.5mEq/l; meaningful conclusions cannot be drawn about
ZS-9’s effects in patients with more severe hyperkalemia. This
will be evaluated in the Phase 3 trials of ZS-9. Similarly, only
patients with stage 3 CKD were included in the present study,
and thus results cannot be extrapolated to patients with more
severe CKD. Although RAAS blockade use was not an entry
criterion, more than half of the patients were receiving
an angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker at baseline. This, combined with the lack of
dietary restrictions, suggests that the study setting was
consistent with what clinicians encounter in daily practice.
In conclusion, these results demonstrate that ZS-9 is well-
tolerated and effective at acutely reducing s-Kþ in hyperka-
lemic patients with stable stage 3 CKD. Further study of the
long-term efficacy and safety of ZS-9 to decrease Kþ and
maintain normokalemia in a broader population of patients
with more severe hyperkalemia is ongoing.
MATERIALS AND METHODS
This prospective, double-blind, randomized, placebo-controlled,
multicenter Phase 2 study with three dose cohorts was conducted in
compliance with local and national regulations, Good Clinical
Practice guidelines, and the Declaration of Helsinki Principles
(clinicaltrials.gov NCT01493024, 19 November 2012). All patients
signed informed consent before enrollment. An independent data
safety monitoring committee periodically evaluated accrued safety
data.
Patients
Eligible patients, identified during routine or urgent visits to a
nephrologist or other healthcare providers, were agedX18 years, with
stable Stage 3 CKD, estimated glomerular filtration rate of 30–60ml/
min per 1.73m2 estimated by CKD Epidemiology Collaboration
(CKD-EPI) equation, and mild-to-moderate hyperkalemia (s-Kþ
5.0–6.0mEq/l). Patients with diabetes, heart failure, and hypertension
were allowed; patients were instructed to maintain RAAS inhibitors
and other medications as prescribed during the study, with
compliance monitored by study staff. Exclusion criteria included
pseudohyperkalemia, treatment with oral Kayexalate or phosphate
binders p7 days before enrollment, severe acidosis, acute kidney
injury, and/or hyperkalemia-related electrocardiogram changes.
Randomization and study conduct
Three placebo-controlled dose-escalating cohorts were treated se-
quentially, with X1 week between cohorts to allow the data safety
monitoring committee to evaluate safety/tolerability. A centralized
computer-generated, block randomization scheme was used
(random block size, three or six per site for each cohort). Patients
Table 3 | Treatment-emergent adverse events
ZS-9 dose group
No. (%) of patients
Placebo
(N¼ 30)
0.3 g
(N¼ 12)
3 g
(N¼ 24)
10g
(N¼ 24)
At least one TEAE 3 (10) 1 (8) 3 (13) 8 (33)
Cardiac
Hypertension 0 0 0 1 (4)
Gastrointestinal disorders
Constipation 0 0 1 (4) 0
Diarrhea 0 1 (8) 0 1 (4)
Heartburn 0 0 0 1 (4)
Nausea 1 (3) 0 1 (4) 2 (8)
Vomiting 1 (3) 0 0 3 (13)
Investigations
Aspartate aminotransferase
increased
0 0 1 (4) 0
Nervous system disorders
Headache 1 (3) 0 0 0
Musculoskeletal and connective
tissue disorders
Abdominal cramp 0 1 (8) 0 0
Epigastric tenderness 1 (3) 0 0 0
Right upper quadrant
tenderness
1 (3) 0 0 0
Thigh pain 0 0 0 1 (4)
Vascular disorders
Anemia 0 0 0 1 (4)
Renal and urinary disorders
Urinary tract infection 0 0 1 (4) 2 (8)
TEAEs possibly related to study drug
Constipation — — 1 (mild) —
Nausea 1 (mild) — — —
Vomiting 1 (mild) — — —
Abbreviation: TEAE, treatment-emergent adverse events; ZS-9, sodium zirconium
cyclosilicate.
Note: All TEAEs were mild or moderate in severity, as judged by the investigators,
and the majority were transient in duration; none were considered definitely
related to study drug; there were no serious TEAEs.
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were randomly allocated to ZS-9 or placebo, administered as a
suspension in water t.i.d., in a 2:1 ratio per cohort (cohort 1: n¼ 18
(12–0.3 g ZS-9, 6 to placebo); cohort 2: n¼ 36 (24–3 g ZS-9, 12 to
placebo); cohort 3: n¼ 36 (24–10 g ZS-9, 12 to placebo)).
On Study Day -1 [within 24 h of randomization], patients with
mean s-Kþ5.0-6.0mEq/l (based on three samples collected 30min
apart) were instructed to return to the clinic the next day (Study
Day 0) for baseline estimated glomerular filtration rate determina-
tion (CKD-EPI). If the mean of two estimated glomerular filtration
rate determinations (at 0 and 60min) was within the prespecified
range (40–60ml/min per 1.73m2 for cohort 1; 30–60ml/min per 1.73m2
for 9 of 36 patients in cohort 2; and 30–60ml/min per 1.73m2 for all
other patients in cohorts 2 and 3), the patient was randomized and
returned to the clinic the next day (day 1). Mean baseline s-Kþ
levels were calculated on day 1, on the basis of a weighted average of
the three assessments from Study Day  1 and an additional
assessment on Study Day 1 before the first dose.
During the inpatient treatment phase, patients were treated with
ZS-9 or matching placebo with meals for the first 48 h (days 1–2) to
normalize s-Kþ (3.5–4.9mEq/l). After 48 h (i.e., six doses), patients
with normalized s-Kþ (3.5–4.9mEq/l) were discharged; patients
with elevated s-Kþ (X5.0mEq/l) received an additional day of
treatment. This process was repeated on the morning of day 4.
Patients could receive a minimum of 6 doses of study drug (over 2
days) or a maximum of 12 doses (over 4 days). Patients returned to
the clinic on days 5–7 (the end-of-study visit). Diet was unrestricted;
patients were instructed to maintain normal food intake during the
study. During the inpatient phase, patients were offered the standard
clinic diet or could order food from local restaurants.
Patients could be discontinued from treatment at any time owing
to safety concerns. Safety stopping rules, including treatment
discontinuation if s-Kþ was46.5 oro3.5mEq/l, were prespecified
and shared with the data safety monitoring committee.
Dosage and administration
The 0.3-, 3-, and 10-g doses were selected on the basis of animal oral
toxicity studies and in vitro Kþ binding capacity of ZS-9 (23, data
on file, ZS Pharma). The 3- and 10-g ZS-9 doses were selected to
determine a possible dose–response relationship; the 0.3-g dose was
selected to evaluate a presumed subtherapeutic dose. Placebo was
PROSOLV SMCC 90 (silicified microcrystalline cellulose; JRS
Pharma, Rosenberg, Germany), a tasteless, odorless, water-insoluble,
white powder that is not systemically absorbed and was indis-
tinguishable from ZS-9 suspension.
An unblinded site pharmacist with no other involvement in the
study dispensed placebo (3 g) or ZS-9 (0.3, 3, or 10 g) loaded
approximately 50:50 with Naþ and Hþ in powdered form into an
opaque container; it was mixed with 180ml of water by blinded
clinic staff immediately before administration. Starting on Study
Day 1, patients orally ingested study drug suspensions t.i.d. with
meals (B0800,B1200, andB1800 h±30min), except that on day
1 breakfast was provided at 0930 h (90min after the first dose). The
dosing bottle was sequentially rinsed twice with 30ml of water, and
the patients consumed the rinses. Clinic staff oversaw administra-
tion of the study drug and concomitant medications. No diarrhea-
inducing medications were used.
Assessments
Blood was collected daily, predose, to determine serum chemistry
and hematology parameters; s-Kþ samples were collected at 0.5, 1,
2, and 4 h after the initial dose on day 1 and every 4 h post dose
thereafter. Serum samples were analyzed locally and by the central
laboratory; study eligibility used local laboratory values. A baseline
24-h urine sample was collected starting on day 0 (after rando-
mization patients were sent home with a urine container and
instructed to collect and store their urine until they returned to the
clinic on day 1). On-treatment 24-h urine samples were collected on
day 1 and on each subsequent study day until the patient was
discharged from the clinic.
Outcomes
The primary efficacy end point was the rate of s-Kþ decline in the
first 48 h, using all post-baseline s-Kþ data. Rate of s-Kþ decline
was chosen as a more clinically relevant end point than absolute
change from baseline. Secondary efficacy end points included
changes in s-Kþ at various time points after start of treatment;
secondary pharmacodynamic variables included urine excretion
(Kþ , Naþ ), serum electrolytes (Ca2þ and Mg2þ , Naþ ), and kidney
function parameters (i.e., blood urea nitrogen, serum creatinine,
24-h urea nitrogen and urine creatinine excretion, urinary sediment).
Safety was evaluated by AEs, vital signs, ECGs, and concomitant
medications, and evaluation of clinically relevant chemistry, hema-
tology, and urinalysis parameters.
Statistical methods
The efficacy data included all randomized patients who received
study drug and had s-Kþ determined at least at the 48-h time point
after the start of treatment. The safety population included all
treated patients with any post-baseline safety data. Central labora-
tory values were used for all statistical analyses.
The sample size was determined to provide 90% power to detect
a 0.105 log difference between a ZS-9 dose group and placebo, with
an overall two-sided 5% Type 1 error. For the primary efficacy end
point, treatment groups were compared with placebo using a
prespecified longitudinal model (SAS PROC MIXED, SAS Institute,
Cary, NC) that included all post-baseline s-Kþ during the initial
48 h of treatment. Data were log-transformed and fitted using the
baseline, time, and the dose–time interaction. A closed testing
procedure was prespecified to compare ZS-9 doses with placebo
from the highest to the lowest dose to preserve the Type 1 error.
Treatment groups were also compared using an unpaired t-test for
efficacy and pharmacodynamic end points. Safety data were
summarized descriptively by treatment group.
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Figure S1. ZS-9 recovery in feces of Sprague–Dawley rats.
Figure S2. Potassium excretion in Sprague–Dawley rats (n¼ 20)
administered escalating doses of 2, 4, and 6g ZS-9 (human dose
equivalent of 21, 42, and 62 g/day) for 5 days with a 5-day washout
between each dose escalation.
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